Demonstrated immunogenicity Triggers antibodies against 4 of the most common serogroups of N meningitidis 90% of adults (N=150) had a 4-fold rise in antibody titers after vaccination with MENOMUNE®- A/C/Y/W-1351 Demonstrated clinical benefit Clinical efficacy of 85% or greater has been reported against serogroups A and C meningitis in older children and adults2 Well-tolerated MENOMUNE®-A/C/Y/W-135 can be given at the same time as most immunizations Adverse reactions to meningococcal vaccination are mild and consist principally of pain and redness at the injection site for 1 to 2 days Dosing Adults and children require a single 0.5 mL dose Revaccination of a single 0.5mL dose may be indicated for individuals at high-risk of infection Safety Information MENOMUNE®-A/C/Y/W-135 is indicated for active immunization against invasive meningococcal disease caused by N meningitidis seroproups A, C, Y, and W-135 in persons 2 years of age and older. Protective antibody levels may be achieved within 7 to 10 days after vaccination. As with any vaccine, vaccination with MENOMUNE®-A/C/Y/W-135 may not protect 100% of susceptible individuals. ENOMUNE®-A/C/Y/W-135 will not stimulate protection against infection caused by N meningitidis other than serogroups A, C, Y and W-135. Local adverse reactions may include pain, redness and swelling at the site of injection. There is a low incidence of systemic adverse reactions including headache, malaise, chills, and fever. Immunization with MENOMUNE®-A/C/Y/W-135 should be deferred during any acute illness. MENOMUNE®-A/C/Y/W-135 is contraindicated in persons with known hypersensitivity to any component of the vaccine (including thimerosal). MENOMUNE®-A/C/Y/W-135 is available in 10-dose vials. For individuals sensitive to thimerosal, use the single-dose vial recontituted with preservative-free diluent vial provided. Click to view full Prescribing Information for MENOMUNE®-A/C/Y/W-135. MENOMUNE®-A/C/Y/W-135 is manufactured and distributed by Aventis Pasteur Inc. References: 1. Hankins WA, Gwaltney JM Jr, Hendley JO, et al. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135 (41306). Exp Biol Med. 1982;169:54-57. 2. MENOMUNE®–A/C/Y/W-135.